| Summary: | This equity research has the purpose of projecting Novo Nordisk’s operations within the next5 years. There is a growing trend in the company’s focus towards the GLP-1 segment, shifting away from the traditional focus on in sulinglargine. In addition, there is a perception that insulin industry competitors have not suffered a great incidence from the crisis of the pandemic. To evaluate this, we have created a sales-driven financial model for our projections. The end result of as hare price of DKK816.46(10.54% expected return on its current share price)and the sales composition change observed, supports the fore mentioned hypotheses.
|
|---|